Stock Traders Purchase Large Volume of Call Options on Forte Biosciences (NASDAQ:FBRX)

Posted by Geri Gentry on May 14th, 2026

Forte Biosciences, Inc. (NASDAQ:FBRX – Get Free Report) was the target of some unusual options trading on Wednesday. Stock traders bought 30,205 call options on the company. This represents an increase of approximately 1,663% compared to the average daily volume of 1,713 call options.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on FBRX shares. Wall Street Zen downgraded Forte Biosciences from a “sell” rating to a “strong sell” rating in a report on Sunday. Weiss Ratings restated a “sell (e+)” rating on shares of Forte Biosciences in a report on Friday, March 27th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $67.00.

Get Our Latest Report on FBRX

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of FBRX. Orbimed Advisors LLC boosted its position in Forte Biosciences by 101.8% during the second quarter. Orbimed Advisors LLC now owns 1,196,955 shares of the company’s stock valued at $15,477,000 after purchasing an additional 603,867 shares during the last quarter. Federated Hermes Inc. boosted its position in Forte Biosciences by 52.5% during the third quarter. Federated Hermes Inc. now owns 1,635,380 shares of the company’s stock valued at $24,531,000 after purchasing an additional 563,147 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in Forte Biosciences during the second quarter valued at approximately $4,310,000. Cable Car Capital LP lifted its position in shares of Forte Biosciences by 127.7% in the second quarter. Cable Car Capital LP now owns 500,000 shares of the company’s stock valued at $6,465,000 after buying an additional 280,396 shares during the last quarter. Finally, Jain Global LLC acquired a new stake in shares of Forte Biosciences in the fourth quarter valued at approximately $5,520,000. 77.63% of the stock is owned by institutional investors and hedge funds.

Forte Biosciences Price Performance

FBRX stock opened at $24.66 on Thursday. The stock has a market capitalization of $342.53 million, a P/E ratio of -5.31 and a beta of 3.01. The business has a 50-day moving average of $27.84 and a 200-day moving average of $25.44. Forte Biosciences has a fifty-two week low of $6.70 and a fifty-two week high of $35.80.

Forte Biosciences (NASDAQ:FBRX – Get Free Report) last posted its quarterly earnings data on Monday, May 11th. The company reported ($1.24) earnings per share for the quarter, missing the consensus estimate of ($1.16) by ($0.08). Equities analysts expect that Forte Biosciences will post -4.63 EPS for the current year.

About Forte Biosciences

(Get Free Report)

Forte Biosciences, Inc is a clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome. Headquartered in San Diego, California, Forte leverages proprietary platforms to discover and advance topical live biotherapeutic products and skin barrier therapies aimed at addressing serious dermatological conditions.

The company’s lead product candidate, FB-401, is a topical live biotherapeutic formulation designed to rebalance the skin microbiome in patients with atopic dermatitis.

Receive News & Ratings for Forte Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forte Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.